2016 Fiscal Year Final Research Report
Molecular targeted medicine to inhibit cancer stemness
| Project/Area Number |
26293196
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Saitama Medical University (2015-2016)
Niigata University (2014) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
矢野 聖二 金沢大学, がん進展制御研究所, 教授 (30294672)
梅津 哉 新潟大学, 医歯学総合病院, 准教授 (50251799)
土田 正則 新潟大学, 医歯学系, 教授 (60293221)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | DDX3X / Wnt/β-catenin / VEGF |
|---|
| Outline of Final Research Achievements |
EGFR-TKI has led to unprecedented results in lung cancer patients harboring activating EGFR mutations. However, the phenotypic diversity of cancer cells results in the survival of treatment-resistant cells. DDX3X is a RNA helicase and is involved in Wnt/β-catenin signal activation. We identified lung cancer cells that expressed DDX3X achieve cancer stem cell-like and mesenchymal properties resulting in EGFR-TKI resistance. Response rate of DDX3X positive EGFR mutant lung cancer patients was only 13.3 %. In this study, we demonstrated that Wnt/β-catenin or VEGFR signal inhibitors exhibited synergistic antitumor reactivity to break EGFR-TKI resistance. Clinical sample analyses revealed that DDX3X expression was accompanied withβ-catenin and VEGFR-2 expression. Our data indicate a novel mechanism how lung cancer cells harboring EGFR-activating mutations survive through EGFR-TKI treatment and have a clinical implication to develop a novel treatment for VEGFR- and β-catenin-signaling.
|
| Free Research Field |
呼吸器内科
|
